US Patent

US9891239 — Modulators of pharmacokinetic properties of therapeutics

Method of Use · Assigned to Gilead Sciences Inc · Expires 2029-09-03 · 3y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a compound and its therapeutic methods, including administration with at least one additional therapeutic agent.

USPTO Abstract

The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-257 Tybost
U-257 Tybost

Patent Metadata

Patent number
US9891239
Jurisdiction
US
Classification
Method of Use
Expires
2029-09-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.